



Corporate Presentation

PIONEERING CELLULAR
MEDICINES FOR
WOMEN'S HEALTH

Targeting Ovarian Cancer and Endometriosis

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD. ACN: 602 297 807


SEPTEMBER 2025



Leading with a Legacy of Excellence



Prof. Alan Trounson AO
CEO and President



Pioneered and commercialized IVF.



President of California Institute for Regenerative Medicine.
Led and managed US\$3 Billion fund.



International stem cell expert.

“ Alan Trounson is ranked among the world’s most prominent scientists ”

Research.com (April 2022)

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

The Crippling Burden of Neglected Women's Health

A Two-Part Crisis in Women's Health: A Lethal Cancer and a Debilitating Disease.

1

Ovarian Cancer: A Lethal Disease of Late Diagnosis

- One of the deadliest gynaecological cancers with ~325,000 new cases diagnosed and ~200,000 deaths globally each year.
- Severely limited treatment options, especially for late-stage diagnoses.
- Over 75% of women are diagnosed at a late stage (III/IV).
- 5-year survival rate for stage III is 41% and only 20% for stage IV. [1]

2

Endometriosis: The Widespread and Overlooked Cancer Precursor

- Affects 190 million women globally.
- A leading cause of debilitating pain, organ damage, and infertility.
- Current treatments are inadequate: invasive surgery or hormonal therapies with significant side effects.
- There is no cure.
- Endometriosis is a risk factor for ovarian cancer.

Evidence suggests a strong link between ovarian cancer and endometriosis, and they may have overlapping biology. Cartherics is developing therapies that target specific antigens common to both diseases.



- **Key Takeaway:** Our strategy leverages a de-risked entry in ovarian cancer as a gateway to treating the broader endometriosis crisis.

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.


Landmark 2024 JAMA Study Confirms a Direct Link Between Endometriosis and Ovarian Cancer

Women with severe endometriosis have up to a 19-fold higher risk of developing specific types of ovarian cancer.

Our Gateway to a Massive Market:

1. **Start with Ovarian Cancer:** We will first pursue approval in ovarian cancer, which can qualify for Orphan Drug Status. This provides significant regulatory and commercial advantages, including market exclusivity and a clearer regulatory path. Our initial development is de-risked by focusing on this indication to establish crucial clinical safety and dose data.
2. **Establish a Safety Bridge:** Success in the ovarian cancer trial will provide the critical human safety data required for the platform.
3. **Bridge to the Broader Market:** This safety data provides a gateway to rapidly expand into the much larger endometriosis market (**190 million women worldwide**), where the underlying disease drivers may be shared. For this chronic, non-malignant disease, the toxic payloads of ADCs and Radiopharmaceuticals are unsuitable, creating a significant opportunity for a potent therapy with a superior safety profile like our CAR-NK cells.

TF CAR-NK cells destroying an endometriosis spheroid



Cartherics' engineered iNK Cells rapidly killing endometriosis spheroid.
[Click here for video of TF CAR-NK cells rapidly killing endometriosis spheroid](#)

Control: iNK Cells without TF CAR.
[Click here for Video of Unmodified NK cells showing no effect on endometriosis spheroid](#)

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Our Solution:


A Scalable, "Off-the-Shelf" Cellular Medicine Platform

Pioneering a New Standard in Women's Health:
A Platform Built on Safety, Potency, and Accessibility.




STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

CTH-401: Achieves Potent and Sustained Anti-Tumor Activity in an IP Ovarian Cancer Model



Cancer shown in blue-red increasing



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Solid Foundation for Clinical Execution

Validated, Funded, and Ready to Execute.

Significant Backing



- >A\$79M raised to date from private capital, competitive grants and R&D tax incentives.

State-of-the-Art R&D and Manufacturing Infrastructure



- Operating from a dedicated 1,800m² purpose-built facility.
- New GMP clean rooms mid-2025 to drive our clinical programs forward.

World-Class, Experienced Team



- Led by recognized pioneers in reproductive medicine and biotechnology.

Hospitals where we have clinical advisors and anticipated Phase I/IIa study sites:



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Legacy Opportunity in Women's Health

An Opportunity to Transform Women's Health.

We are seeking help to advance a new generation of cellular medicines for diseases that devastate the lives of millions of women.



The Inflection Point

We are approaching the critical juncture of initiating the first-in-human clinical trials for our lead therapy. This is the pivotal step that translates a decade of pioneering Australian research into a potential cure for ovarian cancer and a new treatment for endometriosis

The Impact

This is more than an investment in a company; it is a philanthropic opportunity to accelerate a paradigm shift in women's health. Success in this trial will create a legacy of hope and serve our duty as "custodians for the next generation"

A Shared Vision

We invite you to join us in creating the "measurable, lasting change" that defines the mission of SMART Collective. A cornerstone partnership at this stage will be the catalyst that brings this life-saving therapy from the laboratory to the patients who desperately need it.

Join us in
transforming the
standard of care
for women's
health

Contact Details

CARTherics

Prof Alan Tounson

Chief Executive Officer
alan.tounson@cartherics.com

Dr Ian Nisbet

Chief Operating Officer
ian.nisbet@cartherics.com

CARTHERICS PTY LTD
12 Ferntree Place
Notting Hill VIC 3168
AUSTRALIA
(ACN 602 297 807)



cartherics.com



[linkedin.com/company/cartherics-pty-ltd/](https://www.linkedin.com/company/cartherics-pty-ltd/)



[youtube.com/watch?v=6tOtMMDals&t=10s](https://www.youtube.com/watch?v=6tOtMMDals&t=10s)

TERRAINCAPITAL

Corporate Advisor

Dominic Marinelli
Terrain Capital Limited
8 Chapel Street,
Richmond, VIC 3121
M: +61 405 269 536
dmarinelli@terraincapital.com

